260 related articles for article (PubMed ID: 18076215)
1. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine.
Becker RH; Frick AD
Clin Pharmacokinet; 2008; 47(1):7-20. PubMed ID: 18076215
[TBL] [Abstract][Full Text] [Related]
2. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus.
Wilde MI; McTavish D
Drugs; 1997 Oct; 54(4):597-614. PubMed ID: 9339963
[TBL] [Abstract][Full Text] [Related]
3. Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine.
Ulrich H; Snyder B; Garg SK
Vasc Health Risk Manag; 2007; 3(3):245-54. PubMed ID: 17703632
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics and pharmacodynamics of insulin aspart.
Lindholm A; Jacobsen LV
Clin Pharmacokinet; 2001; 40(9):641-59. PubMed ID: 11605714
[TBL] [Abstract][Full Text] [Related]
5. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
Becker RH; Frick AD; Burger F; Potgieter JH; Scholtz H
Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977
[TBL] [Abstract][Full Text] [Related]
6. Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes.
Garg SK; Ellis SL; Ulrich H
Expert Opin Pharmacother; 2005 Apr; 6(4):643-51. PubMed ID: 15934890
[TBL] [Abstract][Full Text] [Related]
7. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period.
Luzio S; Peter R; Dunseath GJ; Mustafa L; Owens DR
Diabetes Res Clin Pract; 2008 Feb; 79(2):269-75. PubMed ID: 18164094
[TBL] [Abstract][Full Text] [Related]
8. Insulin glulisine.
Cox SL
Drugs Today (Barc); 2005 Jul; 41(7):433-40. PubMed ID: 16193096
[TBL] [Abstract][Full Text] [Related]
9. Insulin lispro: its role in the treatment of diabetes mellitus.
Campbell RK; Campbell LK; White JR
Ann Pharmacother; 1996 Nov; 30(11):1263-71. PubMed ID: 8913409
[TBL] [Abstract][Full Text] [Related]
10. Insulin glulisine.
Robinson DM; Wellington K
Drugs; 2006; 66(6):861-9. PubMed ID: 16706558
[TBL] [Abstract][Full Text] [Related]
11. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes.
Plank J; Wutte A; Brunner G; Siebenhofer A; Semlitsch B; Sommer R; Hirschberger S; Pieber TR
Diabetes Care; 2002 Nov; 25(11):2053-7. PubMed ID: 12401756
[TBL] [Abstract][Full Text] [Related]
12. Insulin glulisine: a review of its use in the management of diabetes mellitus.
Garnock-Jones KP; Plosker GL
Drugs; 2009 May; 69(8):1035-57. PubMed ID: 19496630
[TBL] [Abstract][Full Text] [Related]
13. Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes.
Bolli GB; Luzio S; Marzotti S; Porcellati F; Sert-Langeron C; Charbonnel B; Zair Y; Owens DR
Diabetes Obes Metab; 2011 Mar; 13(3):251-7. PubMed ID: 21205115
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes.
Danne T; Becker RH; Heise T; Bittner C; Frick AD; Rave K
Diabetes Care; 2005 Sep; 28(9):2100-5. PubMed ID: 16123473
[TBL] [Abstract][Full Text] [Related]
15. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
Burge MR; Waters DL; Holcombe JH; Schade DS
J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
[TBL] [Abstract][Full Text] [Related]
16. The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications.
Owens DR; Bolli GB
Diabetes Obes Metab; 2020 May; 22(5):743-754. PubMed ID: 31930670
[TBL] [Abstract][Full Text] [Related]
17. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes.
Rave K; Klein O; Frick AD; Becker RH
Diabetes Care; 2006 Aug; 29(8):1812-7. PubMed ID: 16873785
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of insulin glulisine in patients with type 1 diabetes.
Dreyer M; Prager R; Robinson A; Busch K; Ellis G; Souhami E; Van Leendert R
Horm Metab Res; 2005 Nov; 37(11):702-7. PubMed ID: 16308840
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences.
Home PD
Diabetes Obes Metab; 2012 Sep; 14(9):780-8. PubMed ID: 22321739
[TBL] [Abstract][Full Text] [Related]
20. Insulin glulisine: a faster onset of action compared with insulin lispro.
Heise T; Nosek L; Spitzer H; Heinemann L; Niemöller E; Frick AD; Becker RH
Diabetes Obes Metab; 2007 Sep; 9(5):746-53. PubMed ID: 17593235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
